Premas Life Sciences Pvt Ltd has signed an exclusive distribution agreement with IncellDx Inc in India, the company announced on Wednesday.

The commercial partnership will bring together the power of cell by cell multiplex diagnostics for solid tumours carcinomas that can now be analysed for molecular and protein biomarkers by flow cytometry.

IncellDx is a molecular diagnostics company that combines molecular diagnostics with high throughput cellular analysis, focusing on lung, cervical, head and neck, and bladder cancers.

The deal between the two companies includes: IncellDx's patented single-cell assays for quantifying PD-L1 on tumour cells and immune cell subtypes; patented single-cell assay for HPV E6, E7 mRNA detection in cervical samples; and its incellPREP single-cell preparation kit for solid tissues, including tumours.

MD of Premas Life Sciences, Praveen Gupta, believes IncellDx offers a platform for "highly effective companion diagnostics" that will help researchers and patients and could aid in tackling the increasing cancer burden in India.